Study to Evaluate the Tolerance and Pharmacokinetics of Suramin Sodium

A Randomized, Double-blind, Placebo-controlled, Single-dose, Dose-escalation Study to Evaluate the Tolerance and Pharmacokinetics of Suramin Sodium in Healthy Chinese Adults

This is a randomized, double-blind, placebo-controlled, single-dose with three incremental doses, Phase 1 study to evaluate the tolerance and pharmacokinetics of suramin sodium for injection in Chinese healthy adults.

Study Overview

• Status: Unknown
• Conditions: Hand, Foot and Mouth Disease
• Intervention / Treatment: Drug: suramin sodium; Other: placebo

Detailed Description

A total of 36 subjects are divided into three dosage groups: 10mg/kg, 15mg/kg and 20mg/kg, in which 20mg/kg is the conventional dosage per international pharmacopoeias for established indications of suramin sodium. Each dose group contains 12 subjects. By randomization, 10 of them receive suramin sodium while 2 of them receive placebo (0.9% sodium chloride injection）. The trial will start from the low dose (10mg/kg) group, followed by the middle dose (15mg/kg) and high dose (20mg/kg) groups, only after the safety in the previous dose group has been demonstrated.

All subjects in each dose group will be un-blinded after blood/urine collection and safety evaluation on Day 28. After that, blood and urine samples on suramin-dosing subjects will continue to collect on Days 56、84、112 and 140.

Subjects receiving placebo will complete the study on Day 28 if no AE is observed, or follow up till the adverse event (AE) return to normal or stabilize if AE is detected.

Blood and urine samples will be tested by a validated LC/MS method for pharmacokinetic study.

• Study Type: Interventional
• Enrollment (Anticipated): 36
• Phase: Phase 1

Contacts and Locations

Study Locations

• China
  • Zhejiang
    • Hangzhou, Zhejiang, China
      • Recruiting
      • First affiliated Hospital of Zhejiang University
      • Contact: Jianzhong Shentu, Ph.D.（Pharm）; Phone Number: 0571 87236560; Email: stjz@zju.edu.cn

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 45 years (Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

1. Healthy volunteers who fully understand the purpose, content, benefits and possible adverse reactions of the test and voluntarily sign written informed consent prior to the commencement of any test-related activities.
2. Healthy males or females, aged 18 to 45 years (including 18 and 45 years).
3. Male subjects weighed 50-75 kg (including 50 and 75 kg), female subjects weighed 45-75 kg (including 45 and 75 kg), body mass index (BMI) was 18.0-26.0 kg/m2 (including 18.0 and 26.0 kg/m2), where BMI = body weight (kg)/height2 (m2).
4. Have the ability to communicate with investigator and abide by the management regulations of the hospital and the clinical research.

Exclusion Criteria:

1. Fail in physical examination, vital signs measurement, standard 12-lead electrocardiogram, chest X-ray, laboratory examination [blood routine, urine routine, blood biochemistry, blood coagulation function, infectious diseases, blood pregnancy (only for women of childbearing age), as judged by the investigator to be of clinical significance.
2. With gastrointestinal tract, kidney, liver, nerve, blood, endocrine, tumor, lung, immunity, mental or cardiovascular diseases.
3. Has allergic constitution (allergic to two or more substances), or allergic history, or known allergic to suramin sodium.
4. Cannot tolerate venipuncture and/or have a history of fainting blood or needle.
5. Has massive blood loss (> 400 mL) or had donated blood/blood components within the first six months of screening, or who planned to donate blood/blood components during the study period.
6. Had participated in clinical trials of drugs and took research drugs within three months before screening.
7. Smoke more than five cigarettes a day (including nicotine substitutes) or the same amount of tobacco products in the first three months of screening.
8. Has history of drug abuse within 5 years before screening, or those who had used drugs within 3 months before screening.
9. Has a history of alcoholism or moderate alcoholism in the first two years of screening (moderate alcoholism is defined as drinking more than 3 units per day or 21 units per week; a bottle of 350 mL beer, 120 mL white wine, 150 mL wine or 30 mL spirits is one unit).
10. Pregnant or lactating women, or subjects (or their partners) who have pregnancy plans during the trial and within three months after the end of the study, or who do not agree to use non-drug contraceptive measures during the trial.
11. Positive urine drug screening in screening stage.
12. Alcohol urine positive in screening stage.
13. Nicotine positive in screening stage.
14. With acute diseases in screening period.
15. Had used any prescription, over-the-counter, vitamin products or Chinese herbal medicines within 14 days before enrollment.
16. Female subjects of childbearing age who did not take non-drug contraceptive measures within 14 days before admission.
17. Not suitable for participating into the trial as judged by the investigator.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Triple

Number of Arms

6

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Group 1-1; The dose of suramin sodium is 10 mg/kg	Drug: suramin sodium; The trial will start from the low dose (10mg/kg) group, followed by the middle dose (15mg/kg) and high dose (20mg/kg) groups, only after the safety in the previous dose group has been demonstrated.。
Placebo Comparator: Group 1-2; The placebo is 0.9% sodium chloride injection	Other: placebo; Placebo is 0.9% sodium chloride injection.; Other Names: 0.9% sodium chloride injection
Experimental: Group 2-1; The dose of suramin sodium is 15mg/kg	Drug: suramin sodium; The trial will start from the low dose (10mg/kg) group, followed by the middle dose (15mg/kg) and high dose (20mg/kg) groups, only after the safety in the previous dose group has been demonstrated.。
Placebo Comparator: Group 2-2; The placebo is 0.9% sodium chloride injection	Other: placebo; Placebo is 0.9% sodium chloride injection.; Other Names: 0.9% sodium chloride injection
Experimental: Group 3-1; The dose of suramin sodium is 20mg/kg	Drug: suramin sodium; The trial will start from the low dose (10mg/kg) group, followed by the middle dose (15mg/kg) and high dose (20mg/kg) groups, only after the safety in the previous dose group has been demonstrated.。
Placebo Comparator: Group 3-2; The placebo is 0.9% sodium chloride injection	Other: placebo; Placebo is 0.9% sodium chloride injection.; Other Names: 0.9% sodium chloride injection

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Number of subjects with adverse events	Adverse events	[ Day 1 to Day 140 ]
the area under the plasma concentration-time curve (AUC) from time zero to the time of the last measurable concentration (AUC0-t) of suramin sodium	Pharmacokinetics parameters	[ Day 1 to Day 140 after study drug administration ]
the AUC from time zero to infinity (AUC0-inf) of suramin sodium	Pharmacokinetics parameters	[ Day 1 to Day 140 after study drug administration ]
maximum plasma concentration (Cmax ) of suramin sodium	Pharmacokinetics parameters	[ Day 1 to Day 140 after study drug administration ]
half life （t1/2） of suramin sodium	Pharmacokinetics parameters	[Day 1 to Day 140 after study drug administration ]
clearance （CL） of suramin sodium	Pharmacokinetics parameters	[ Day 1 to Day 140 after study drug administration ]
apparent volume of distribution（Vd） of suramin sodium	Pharmacokinetics parameters	[ Day 1 to Day 140 after study drug administration ]
the amount of drug excreted into the urine from time zero to time 7 days（Ae0-t） of suramin sodium	Pharmacokinetics parameters	[ Day 1 to Day 7 after study drug administration ]

Collaborators and Investigators

• Sponsor: First Affiliated Hospital of Zhejiang University
• Collaborators: Guangdong Kangda Pharmaceutical Co., Ltd
• Investigators: Principal Investigator: First Affiliated Hospital Zhejiang University, First affiliated Hospital of Zhejiang University

Study record dates

Study Major Dates

• Study Start (Actual): December 19, 2018
• Primary Completion (Anticipated): December 19, 2019
• Study Completion (Anticipated): December 19, 2020

Study Registration Dates

• First Submitted: December 28, 2018
• First Submitted That Met QC Criteria: January 11, 2019
• First Posted (Actual): January 15, 2019

Study Record Updates

• Last Update Posted (Actual): January 15, 2019
• Last Update Submitted That Met QC Criteria: January 11, 2019
• Last Verified: January 1, 2019

More Information

Terms related to this study

• Keywords: suramin sodium
• Additional Relevant MeSH Terms: RNA Virus Infections; Virus Diseases; Infections; Stomatognathic Diseases; Enterovirus Infections; Picornaviridae Infections; Coxsackievirus Infections; Mouth Diseases; Foot-and-Mouth Disease; Hand, Foot and Mouth Disease; Anti-Infective Agents; Antineoplastic Agents; Antiprotozoal Agents; Antiparasitic Agents; Antinematodal Agents; Anthelmintics; Trypanocidal Agents; Suramin
• Other Study ID Numbers: LC00-043

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: No

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No